China's HNG, India's Ranbaxy End Alliance, China Drug-Making
This article was originally published in PharmAsia News
China's HNG Chembio Pharmacy has lost its long-time partner, India's Ranbaxy Laboratories and its Guang-zhou Baiyunshan Pharmaceutical subsidiary
You may also be interested in...
MUMBAI - For large Indian drug companies, China has been a traditional and, to an extent, a dreaded rival in the business of pharmaceutical raw materials. Gargantuan Chinese factories that cropped up in the eighties almost killed scores of Indian bulk drug manufacturing units as every pricing strategy the Indian outfits could conceive of failed to beat the quotations offered by Chinese manufacturers to global brand name companies
FDA launches what it hopes will the final push to reform the regulatory oversight system for lab-developed tests by proposing a relatively rapid transition period to require essentially all LDTs to comply with the existing regulations for in vitro diagnostics. Legislation, litigation, and industry negotiation will likely shape the final product.
Signing a deal worth up to $1.5bn, Teva is hoping Sanofi’s dominance in immunology via the mega-blockbuster Dupixent can help it compete with frontrunners Pfizer/Roivant and Merck & Co in a new anti-inflammatory space.